Markets
President Trump Signs Executive Orders At The White House
President Donald Trump signs executive orders in the Oval Office (Alex Wong/Getty Images)
The noise is the signal

For markets, Trump’s tariff threats are quantitative easing in reverse

Every minute Trump spends talking about tariffs, he’s not talking about tax cuts or deregulation to juice an economy and a stock market that are losing momentum.

Luke Kawa

Tariff talk is playing a role in the S&P 500’s near 10% decline from all-time highs, but probably not in the way you might think.

In fact, what the seemingly incessant barrage of tariff threats (and walk-backs) is doing to contribute to this retreat appears analogous to claims of how the Federal Reserve’s quantitative easing drives upside in stocks — only in reverse.

Arguments that bond-buying programs by the Federal Reserve are a crucial linchpin for the direction of stock market range from the rudimentary and mechanically flawed (“pumping money into the stock market”) to the more advanced but difficult to quantify (portfolio rebalancing channel, which seems to work best in helping to tighten credit spreads).

Zooming out, the stock market has gone up while the Federal Reserve’s balance sheet is growing. The stock market has also gone up with the Federal Reserve’s balance sheet contracting. There is no magic cheat code here.

What quantitative easing accomplishes is that it offers a signal to the market that monetary policy is locking in to a prolonged period of providing support for the economy and financial system. Simply, if the Federal Reserve is buying bonds, it’s a helluva long way from raising rates.

To compare this to tariffs, every minute US President Donald Trump spends musing about tariffs is a minute he isn’t talking about deregulation or tax cuts. It’s a revealed preference on where his priorities lie. It’s a signal that policy is not pointed in a pro-growth direction.

And he is talking about tariffs. A lot.

Tariffs are a signal of what has been said explicitly by Treasury Secretary Scott Bessent: in Trump 2.0, the stock market is not the administration’s report card (for now, at least). And the near-term performance of the economy might not be, either.

The trend for nominal growth is lower, and the Trump administration is signaling — through tariff talks, DOGE, and more — that they should not be expected to serve as a catalyst for any inflection higher in activity. If you’re a US stock bull living in a world in which the premium profit growth generated by megacap tech companies and AI-linked names is also off the boil, tariff chatterings are not the tape bombs you’re looking for.

This choice of priorities is both disturbing and surprising to a market where measures of consumer confidence jolted higher in the wake of the election, in part due to memories of Trump 1.0 policy sequencing: tax cuts first, prosecute a trade war against China second.

There should be no doubt in how this sell-off started: a breakdown in momentum stocks catalyzed by Walmart’s underwhelming guidance that kneecapped an AI trade which had enjoyed great success and become richly priced.

Momentum stocks fell 5% and Technology Select Sector SPDR was down 7%, while Financial Select Sector SPDR Fund, which is much more sensitive to perceived ebbs and flows in US economic activity, traded flat. AI infrastructure names like Arista Networks were down 10% while Bank of America was up. These are not things you would expect to see if fears about economic growth were the proximate cause of the market’s initial decline — they weren’t.

That any growth scare means high-flying stocks get dumped the most is far from a hard-and-fast rule, and not borne out by most market corrections or bear markets of note over the past decade (exception: 2022). In the 2015-16 sell-off, which occurred amid a US industrial recession due to the shale bust coupled with fears of a hard landing in China, momentum and tech outperformed and financials underperformed. Even in the Q4 2018 tumble, which bore many more hallmarks of a messy long-short deleveraging, cyclical stocks still did worse than momentum. Same thing through the Covid-induced market crash.

In March, we’ve seen an evolution in the sell-off, with financials tumbling (though still not doing as badly as momentum) and a noteworthy widening in credit spreads. Growth fears have clearly earned their place as the best supporting actor in this horror flick, and may well ascend to a leading role.

What role are tariffs playing in exacerbating worries about an economic downturn? Well, there’s certainly something there, with a basket of stocks compiled by Goldman Sachs judged to be most sensitive to levies underperforming a group deemed tariff-immune by a little less than 2% since the S&P 500’s record close on February 19. 

But a look at the performance of General Motors and Ford during this stretch should raise questions about how potent of a catalyst this is. One of the first rules of risk management is that if you don’t know what’s going on, you reduce risk. There is no reason why those automakers, perhaps the companies that would be most disrupted by wide-ranging tariffs against Canada and Mexico, should be immune from this dynamic in a world where concerns about North American tariffs are purportedly escalating. In fact, both are… up during the market’s decline.

I would suggest this means anyone deeming this a tariff-centric sell-off is in the unenviable position of having to also argue that it was efficiently priced in, to GM and Ford at least, before the market’s retreat from all-time highs even began.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets
Luke Kawa

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.